Cas:90-92-6 (2E)-1-(4-methoxyphenyl)-2-[(4-methoxyphenyl)methylidene]butan-1-one manufacturer & supplier

We serve Chemical Name:(2E)-1-(4-methoxyphenyl)-2-[(4-methoxyphenyl)methylidene]butan-1-one CAS:90-92-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(2E)-1-(4-methoxyphenyl)-2-[(4-methoxyphenyl)methylidene]butan-1-one

Chemical Name:(2E)-1-(4-methoxyphenyl)-2-[(4-methoxyphenyl)methylidene]butan-1-one
CAS.NO:90-92-6
Synonyms:2-Aethyl-1,3-bis-(4-methoxy-phenyl)-propenon;2-ethyl-1,3-bis-(4-methoxy-phenyl)-propenone;|A-Ethyl-4,4′-dimethoxychalcone;Chalcone,4′-dimethoxy;1-(4-Methoxyphenyl)-2-[(4-methoxyphenyl)methylene]-1-butanone
Molecular Formula:C19H20O3
Molecular Weight:296.36000
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:460.3ºC at 760 mmHg
Density:1.095g/cm3
Index of Refraction:
PSA:35.53000
Exact Mass:296.14100
LogP:4.38010

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2-Aethyl-1,3-bis-(4-methoxy-phenyl)-propenon chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-(4-Methoxyphenyl)-2-[(4-methoxyphenyl)methylene]-1-butanone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Aethyl-1,3-bis-(4-methoxy-phenyl)-propenon Use and application,2-ethyl-1,3-bis-(4-methoxy-phenyl)-propenone technical grade,usp/ep/jp grade.


Related News: In the trial, 362 eligible patients were randomised (1:1) and received a fixed-dose intravenous infusion of 300mg anifrolumab or placebo every four weeks. 2-methyl-1,3,5-hexatriene manufacturers Given ICER’s uncertainty regarding efgartigimod’s dosing and long-term benefits, the group said it’s moderately certain the drug can produce a “comparable, small or substantial net health benefit” in that same group of MG patients. butyl 4-(2-butoxyphenyl)-2-methyl-5-oxo-1,4,6,7,8-pentahydroquinoline-3-carboxylate suppliers AstraZeneca acquired global rights to anifrolumab through an exclusive license and collaboration agreement with Medarex, Inc. in 2004. Medarex was acquired by Bristol-Myers Squibb in 2009. 5-nitro-1-SEM-2,4(1H,3H)pyrimidinedione vendor & factory.